LabStyle Innovations, Creator of Dario™ Diabetes mHealth Solution to Webcast, Live, at RetailInvestorConferences.com June 5th LabStyle invites individual and institutional investors to attend interactive real-time presentation on how mHealth can make life easier for people with diabetes and other chronic diseases.

NEW YORK, June 2, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario™ Diabetes mHealth Solution, today announced that its President and Chief Executive Officer, Mr. Erez Raphael, will present at RetailInvestorConferences.com on June 5th.

DATE:  Thursday, June 5, 2014

TIME:   9:15 AM EDT

LINK:   http://retailinvestorconferences.com > red "register/ watch event now" button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Recent LabStyle Innovation Highlights:

  • First shipments of the Dario™ Diabetes Management Solution in Italy, New Zealand and the United Kingdom, collecting initial positive feedback.
  • Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the Dario™ Personalized Smart Meter.
  • National and regional insurance reimbursement approval for the Dario™ Personalized Smart Meter in Italy.  LabStyle is actively seeking reimbursement in other strategic territories.
  • Work with FDA towards potential clearance of the Dario™ Personalized Smart Meter in the U.S. following a 510K filing made in late December 2013.

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ personalized Diabetes mHealth Solution.   Dario™ received CE mark certification in September 2013 and began a world rollout of the Dario™ mobile application in select countries in December 2013, and initial launches of the full Dario™ solution have commenced in Europe, Australia and New Zealand during 2014.  LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013.  LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services, and in April 2014 LabStyle received a Notice of Allowance for a U.S. patent covering core functions of the Dario™ Blood Glucose Monitoring System. For more information: www.mydario.com and http://mydario.investorroom.com.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

SOURCE LabStyle Innovations Corp.



RELATED LINKS
http://www.mydario.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.